Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan-Kettering Cancer Center, New York

Memorial Sloan Kettering Cancer Center, New York

Charité - Universitaetsmedizin Berlin, Charité Campus Mitte, Berlin

Nemocnice Na Bulovce, Prague

Fox Chase Cancer Center, Philadelphia

Fondazione IRCCS, Istituto Nazionale Tumori, Laboratorio, Milan

Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo, Milan

Johns Hopkins University, Baltimore

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Taichung Veterans General Hospital, Taichung

The Cleveland Clinic, Cleveland

University of Michigan Health System, Ann Arbor

University of Wisconsin - Hospital and Clinics, Madison

University of Chicago Hospitals, Chicago

Hopital de la Pitie Salpetriere, Paris

The University of Texas M.D. Anderson Cancer Center, Houston

The University of Texas MD Anderson Cancer Center, Houston

Fakultni nemocnice Olomouc, Olomouc

UCLA Hematology-Oncology-Santa Monica, Santa Monica

UC Irvine Medical Center, Orange

University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Providence Regional Medical Center Everett - Providence Regional Cancer Partnership, Everett

Providence Regional Medical Center Everett, Everett

"FSBSI N.N. Blokhin Russian Cancer Research Center", Moscow

National Cancer Center Hospital East, Kashiwa

Kinki University Hospital, Sayama

Chiba Cancer Center, Chiba

Kyushu University Hospital, Fukuoka

Nagasaki University Hospital, Nagasaki

Samsung Medical Center, Seoul

Nottingham City Hospital / Oncology Department, Nottingham